NEW YORK (GenomeWeb News) – Australian diagnostics and biopharmaceutical firm Agenix announced today it is licensing a rapid point-of-care diagnostic technology from Tyrian Diagnostics for development of a microarray device.

Agenix will use Tyrian's DiagnosticIQ platform for human applications. Bayer CropScience currently licenses the technology for agricultural applications.

Agenix is providing Tyrian A$500,000 (US$517,000) in shares of its stock to be paid in installments through June 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.